Mayne Pharma Group Ltd
ASX:MYX
Mayne Pharma Group Ltd
Revenue
Mayne Pharma Group Ltd
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Mayne Pharma Group Ltd
ASX:MYX
|
Revenue
AU$190.3m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
N/A
|
|
Recce Pharmaceuticals Ltd
ASX:RCE
|
Revenue
AU$6.8m
|
CAGR 3-Years
104%
|
CAGR 5-Years
34%
|
CAGR 10-Years
N/A
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Revenue
AU$237.6m
|
CAGR 3-Years
550%
|
CAGR 5-Years
77%
|
CAGR 10-Years
47%
|
|
Botanix Pharmaceuticals Ltd
ASX:BOT
|
Revenue
AU$588.4k
|
CAGR 3-Years
56%
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
|
Probiotec Ltd
ASX:PBP
|
Revenue
AU$221.2m
|
CAGR 3-Years
28%
|
CAGR 5-Years
24%
|
CAGR 10-Years
13%
|
|
C
|
Clarity Pharmaceuticals Ltd
ASX:CU6
|
Revenue
AU$11.7m
|
CAGR 3-Years
59%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Mayne Pharma Group Ltd's Revenue?
Revenue
190.3m
AUD
Based on the financial report for Jun 30, 2023, Mayne Pharma Group Ltd's Revenue amounts to 190.3m AUD.
What is Mayne Pharma Group Ltd's Revenue growth rate?
Revenue CAGR 5Y
-19%
Over the last year, the Revenue growth was 21%. The average annual Revenue growth rates for Mayne Pharma Group Ltd have been -25% over the past three years , -19% over the past five years .